The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: A role for prolactin in atherogenesis?

Journal of Endocrinology

Volumn 208, Issue 2, 2011, Pages 107-117

  Reuwer, Anne Q ^a   Van Eijk, Marco ^a   Houttuijn Bloemendaal, Felicia M ^a   Van Der Loos, Chris M ^a   Claessen, Nike ^a   Teeling, Peter ^a   Kastelein, John J P ^a   Hamann, Jörg ^a   Goffin, Vincent ^b   Von Der Thüsen, Jan H ^a   Twickler, Marcel Th B ^a,c   Aten, Jan ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b INSERM   (France)

^c Lievensberg Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; MESSENGER RNA; PROLACTIN; PROLACTIN RECEPTOR;

ARTICLE; ATHEROGENESIS; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MACROPHAGE; MALE; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CAROTID STENOSIS; COMPUTER SYSTEMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MICROSCOPY, IMMUNOELECTRON; POLYMERASE CHAIN REACTION; PROLACTIN; RECEPTORS, PROLACTIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 78951484919     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-10-0076     Document Type: Article

References (40)

1. Aziz MM, Ishihara S, Rumi MA, Mishima Y, Oshima N, Kadota C, Moriyama I, Li YY, Rahman FB, Otani A et al. 2008 Prolactin induces MFG-E8 production in macrophages via transcription factor C/EBPbeta-dependent pathway. Apoptosis 13 609-620. (doi:10.1007/s10495-008-0201-1)
2. Ben-Jonathan N, LaPensee CR & LaPensee EW 2008 What can we learn from rodents about prolactin in humans? Endocrine Reviews 29 1-41. (doi:10.1210/er.2007-0017)
3. Bresson JL, Jeay S, Gagnerault MC, Kayser C, Beressi N, Wu Z, Kinet S, Dardenne M & Postel-Vinay MC 1999 Growth hormone (GH) and prolactin receptors in human peripheral blood mononuclear cells: relation with age and GH-binding protein. Endocrinology 140 3203-3209. (doi:10.1210/en.140.7.3203)
4. Carvalho-Freitas MI, Rodrigues-Costa EC, Nasello AG, Palermo-Neto J & Felicio LF 2008 In vitro macrophage activity: biphasic effect of prolactin and indirect evidence of dopaminergic modulation. Neuroimmunomodulation 15 131-139. (doi:10.1159/000148196)
5. Chikanza IC & Grossman AB 1996 Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop. Baillière's Clinical Rheumatology 10 199-225. (doi:10.1016/S0950-3579(96)80015-X)
6. Clevenger CV, Russell DH, Appasamy PM & Prystowsky MB 1990 Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. PNAS 87 6460-6464. (doi:10.1073/pnas.87.16.6460)
7. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT & Tomaszewski JE 1995 Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. American Journal of Pathology 146 695-705.
8. Colao A 2008 The GH-IGF-I axis and the cardiovascular system: clinical implications. Clinical Endocrinology 69 347-358. (doi:10.1111/j.1365-2265.2008. 03292.x)
9. Djiane J, Clauser H & Kelly PA 1979 Rapid down-regulation of prolactin receptors in mammary gland and liver. Biochemical and Biophysical Research Communications 90 1371-1378. (doi:10.1016/0006-291X(79)91187-2)
10. Dorshkind K & Horseman ND 2000 The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocrine Reviews 21 292-312. (doi:10.1210/er.21.3.292) (Pubitemid 32275590)
11. Dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC & Gadelha MR 2010 BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (In Press). (doi:10.1038/oby.2010.150)
12. Dunn R & Hicke L 2001 Domains of the Rsp5 ubiquitin-protein ligase required for receptor-mediated and fluid-phase endocytosis. Molecular Biology of the Cell 12 421-435.
13. Galsgaard ED, Rasmussen BB, Folkesson CG, Rasmussen LM, Berchtold MW, Christensen L & Panina S 2009 Re-evaluation of the prolactin receptor expression in human breast cancer. Journal of Endocrinology 201 115-128. (doi:10.1677/JOE-08-0479)
14. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP et al. 2009 Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54 98-105. (doi:10.1161/ HYPERTENSIONAHA.109.132100)
15. Horseman ND 1999 Prolactin and mammary gland development. Journal of Mammary Gland Biology and Neoplasia 4 79-88. (doi:10.1023/A:1018708704335)
16. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ & Goldschmeding R 1998 Expression of connective tissue growth factor in human renal fibrosis. Kidney International 53 853-861. (doi:10.1111/j.1523-1755.1998. 00820.x)
17. Kelly PA, Djiane J, Postel-Vinay MC & Edery M 1991 The prolactin/growth hormone receptor family. Endocrine Reviews 12 235-251. (doi:10.1210/edrv-12-3-235)
18. Kline JB, Rycyzyn MA & Clevenger CV 2002 Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain. Molecular Endocrinology 16 2310-2322. (doi:10.1210/me.2001-0033)
19. Kottke BA 1986 Lipid markers for atherosclerosis. American Journal of Cardiology 57 11C-17C. (doi:10.1016/0002-9149(86)91021-0)
20. van der Loos CM 2008 Multiple immunoenzyme staining: methods and visualizations for the observation with spectral imaging. Journal of Histochemistry and Cytochemistry 56 313-328. (doi:10.1369/jhc.2007.950170)
21. van der Loos CM & Teeling P 2008 A generally applicable sequential alkaline phosphatase immunohistochemical double staining. Journal of Histotechnology 31 119-127.
22. Nicoll CS, Mayer GL & Russell SM 1986 Structural features of prolactins and growth hormones that can be related to their biological properties. Endocrine Reviews 7 169-203. (doi:10.1210/edrv-7-2-169)
23. Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, Marz W, Rupp J, Pech M & Luscher TF 1997 Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 95 831-839.
24. Packard RR & Libby P 2008 Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry 54 24-38. (doi:10.1373/clinchem.2007.097360)
25. Pellegrini I, Lebrun JJ, Ali S & Kelly PA 1992 Expression of prolactin and its receptor in human lymphoid cells. Molecular Endocrinology 6 1023-1031. (doi:10.1210/me.6.7.1023)
26. Reuwer AQ, Nieuwland R, Fernandez I, Goffin V, van Tiel CM, Schaap MC, Berckmans RJ, Kastelein JJ & Twickler MT 2009a Prolactin does not affect human platelet aggregation or secretion. Thrombosis and Haemostasis 101 1119-1127. (doi:10.1160/TH08-12-0801)
27. Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, Bogorad RL, Goffin V, Smink-Bol M, Kastelein JJ et al. 2009b Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circulation. Cardiovascular Genetics 2 389-395. (doi:10.1161/ CIRCGENETICS.109.853572)
28. Rocha VZ & Libby P 2009 Obesity, inflammation, and atherosclerosis. Nature Reviews. Cardiology 6 399-409. (doi:10.1038/nrcardio.2009.55)
29. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ &Moorman AF 2009 Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Research 37 e45. (doi:10.1093/nar/gkp045)
30. Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, Kooijman R, Kutz L, Kelley KW & Malarkey WB 1992 Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. PNAS 89 7713-7716. (doi:10.1073/pnas.89.16.7713)
31. Schwarz LA, Stevens AM, Hrachovy JA & Yu-Lee LY 1992 Interferon regulatory factor-1 is inducible by prolactin, interleukin-2 and concanavalin A in T cells. Molecular and Cellular Endocrinology 86 103-110. (doi:10.1016/0303-7207(92)90180-E)
32. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F & Renier G 2006 The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clinical Endocrinology 64 366-370.
33. Streefkerk JG, de Graaf GA & de Vries RA 1972 Antibody against horse radish peroxidase in lymphoid organs. Acta Morphologica Neerlando-Scandinavica 10 398-399.
34. Stumpe KO, Kolloch R, Higuchi M, Kruck F & Vetter H 1977 Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control. Lancet 2 211-214. (doi:10.1016/S0140-6736(77)92832-X)
35. Swaminathan G, Varghese B, Thangavel C, Carbone CJ, Plotnikov A, Kumar KG, Jablonski EM, Clevenger CV, Goffin V, Deng L et al. 2008 Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. Journal of Endocrinology 196 R1-R7. (doi:10.1677/JOE-07-0554)
36. Varghese B, Barriere H, Carbone CJ, Banerjee A, Swaminathan G, Plotnikov A, Xu P, Peng J, Goffin V, Lukacs GL et al. 2008 Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Molecular and Cellular Biology 28 5275-5287. (doi:10.1128/MCB.00350-08)
37. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G & Akalin S 2003 Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. European Journal of Endocrinology 149 187-193. (doi:10.1530/eje.0.1490187) (Pubitemid 37120990)
38. Yuan C, Zhang S, Polissar NL, Echelard D, Ortiz G, Davis JW, Ellington E, Ferguson MS & Hatsukami TS 2002 Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 105 181-185. (doi:10.1161/hc0202.102121)
39. van Zaane B, Reuwer AQ, Buller HR, Kastelein JJ, Gerdes VE & Twickler MT 2009 Hormones and cardiovascular disease: a shift in paradigm with clinical consequences? Seminars in Thrombosis and Hemostasis 35 478-487. (doi:10.1055/s-0029-1234143)
40. Zhang L, Curhan GC & Forman JP 2010 Plasma prolactin level and risk of incident hypertension in postmenopausal women. Journal of Hypertension 28 1400-1405. (doi:10.1097/HJH.0b013e328339f254)